Reduced Toll-like receptor 3 expression in chronic hepatitis B patients and its restoration by interferon therapy

Antiviral Therapy

Volumn 18, Issue 7, 2013, Pages 877-884

  Huang, Yi Wen ^a,b,c,d   Lin, Shih Chang ^a   Wei, Shu Chen ^c   Hu, Jui Ting ^a,e   Chang, Han Yu ^a   Huang, Shih Hung ^a   Chen, Ding Shinn ^b,c   Chen, Pei Jer ^b,c   Hsu, Ping Ning ^b   Yang, Sien Sing ^a,e   Kao, Jia Horng ^b,c,f  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; MESSENGER RNA; PEGINTERFERON; TOLL LIKE RECEPTOR 3;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENDER; GENE EXPRESSION; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN TISSUE; KUPFFER CELL; LIVER CELL; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; TLR3 GENE; VIRUS STRAIN;

ADULT; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION; GENOTYPE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTERFERONS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TOLL-LIKE RECEPTOR 3;

EID: 84892707497     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2630     Document Type: Article

References (36)

1. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002;2:395-403.
2. Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993;262:369-370.
3. Chisari F V, Ferrari C. Hepatitis B immunopathogenesis. Annu Rev Immunol 1995;13:29-60.
4. Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005;79:7269-7272.
5. Visvanathan K, Skinner NA, Thompson A J V, et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007;45:102-110.
6. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987-995.
7. Ranjith-Kumar CT, Miller W, Xiong J, et al. Biochemical and functional analyses of the human Toll-like receptor 3 ectodomain. J Biol Chem 2007;282:7668-7678.
8. Nahum A, Dadi H, Bates A, Roifman CM. The L412F variant of Toll-like receptor 3 (TLR3) is associated with cutaneous candidiasis, increased susceptibility to cytomegalovirus, and autoimmunity. J Allergy Clin Immunol 2011;127:528-531.
9. Hidaka F, Matsuo S, Muta T, Takeshige K, Mizukami T, Nunoi H. A missense mutation of the Toll-like receptor 3 gene in a patient with inluenza-associated encephalopathy. Clin Immunol 2006;119:188-194.
10. Zhang SY, Jouanguy E, Ugolini S, et al. TLR3 deiciency in patients with herpes simplex encephalitis. Science 2007;317:1522-1527.
11. Bousiha A, Picard C, Boisson-Dupuis S, et al. Primary immunodeiciencies of protective immunity to primary infections. Clin Immunol 2010;135:204-209.
12. Netea MG, Van Der Meer JW. Immunodeiciency and genetic defects of pattern-recognition receptors. N Engl J Med 2011;364:60-70.
13. Al-Qahtani A, Al-Ahdal M, Abdo A, et al. Toll-like receptor 3 polymorphism and its association with hepatitis B virus infection in Saudi Arabian patients. J Med Virol 2012;84:1353-1359.
14. Rong Y, Song H, You S, et al. Association of Toll-like receptor 3 polymorphisms with chronic hepatitis B and hepatitis B-related acute-on-chronic liver failure. Inlammation 2013;36:413-418.
15. Schulz O, Diebold SS, Chen M, et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005;433:887-892.
16. Yeh SH, Tsai CY, Kao JH, et al. Quantiication and genotyping of hepatitis B virus in a single reaction by realtime PCR and melting curve analysis. J Hepatol 2004;41:659-666.
17. Lok A S F, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539.
18. Chen Z, Cheng Y, Xu Y, et al. Expression proiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol 2008;128:400-408.
19. Xie Q, Shen HC, Jia NN, et al. Patients with chronic hepatitis B infection display deiciency of plasmacytoid dendritic cells with reduced expression of TLR9. Microbes Infect 2009;11:515-523.
20. Woltman AM, Op Den Brouw ML, Biesta PJ, Shi CC, Janssen HL. Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PLoS ONE 2011;6:e15324.
21. Xu Y, Hu Y, Shi B, et al. HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. Mol Immunol 2009;46:2640-2646.
22. Heiberg IL, Winther TN, Paludan SR, Hogh B. Pattern recognition receptor responses in children with chronic hepatitis B virus infection. J Clin Virol 2012;54:229-234.
23. Wu J, Meng Z, Jiang M, et al. Hepatitis B virus suppresses Toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009;49:1132-1140.
24. Yu S, Chen J, Wu M, Chen H, Kato N, Yuan Z. Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. J Gen Virol 2010;91:2080-2090.
25. Foster GR, Ackrill AM, Goldin RD, Kerr IM, Thomas HC, Stark GR. Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA. Proc Natl Acad Sci U S A 1991;88:2888-2892.
26. Wu J, Lu M, Meng Z, et al. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 2007;46:1769-1778.
27. Tang TJ, Kwekkeboom J, Laman JD, et al. The role of intrahepatic immune effector cells in inlammatory liver injury and viral control during chronic hepatitis B infection. J Viral Hepat 2003;10:159-167.
28. Liang TJ. Hepatitis B: the virus and disease. Hepatology 2009;49:S13-S21.
29. Huang YW, Chayama K, Tsuge M, et al. Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B. Antivir Ther 2010;15:177-184.
30. Lai Y, Yi G, Chen A, et al. Viral double-strand RNA-binding proteins can enhance innate immune signaling by Toll-like receptor 3. PLoS ONE 2011;6:e25837.
31. Porterield JZ, Dhason MS, Loeb DD, Nassal M, Stray SJ, Zlotnick A. Full-length hepatitis B virus core protein packages viral and heterologous RNA with similarly high levels of cooperativity. J Virol 2010;84:7174-7184.
32. Wang K, Liu H, He Y, et al. Correlation of TLR1-10 expression in peripheral blood mononuclear cells with chronic hepatitis B and chronic hepatitis B-related liver failure. Hum Immunol 2010;71:950-956.
33. Li N, Li Q, Qian Z, Zhang Y, Chen M, Shi G. Impaired TLR3/IFN-beta signalling in monocyte-derived dendritic cells from patients with acute-on-chronic hepatitis B liver failure: relevance to the severity of liver damage. Biochem Biophys Res Commun 2009;390:630-635.
34. Lambotin M, Raghuraman S, Stoll-Keller F, Baumert T F, Barth H. A look behind closed doors: interaction of persistent viruses with dendritic cells. Nat Rev Microbiol 2010;8:350-360.
35. Tjwa ET, Van Oord GW, Biesta PJ, Boonstra A, Janssen HL, Woltman AM. Restoration of TLR3-activated myeloid dendritic cell activity leads to improved natural killer cell function in chronic hepatitis B virus infection. J Virol 2012;86:4102-4109.
36. Chew V, Tow C, Huang C, et al. Toll-like receptor 3 expressing tumor parenchyma and iniltrating natural killer cells in hepatocellular carcinoma patients. J Natl Cancer Inst 2012;104:1796-1807.